highly significantp = 0.007
The overall score on the SALSEX scale between the baseline (5.4 ± 4.3) and follow-up visit (3.9 ± 3.6) was reduced in a highly significant way ( p = 0.007) ( Figure 1 ), showing a clinical improvement in the sexual function of patients who started treatment with desvenlafaxine at follow-up.